Onkolojide Farmakogenetik
Özet
Farmakogenetik, bireyler arasındaki genetik varyasyonların ilaç yanıtları ve yan etkileri üzerindeki etkilerini inceleyerek onkolojide kişiselleştirilmiş tedavi süreçlerinin optimize edilmesini hedefler. Geleneksel onkoloji uygulamalarında somatik mutasyonlar hedefe yönelik tedavilerin belirlenmesinde kullanılırken; germline mutasyonlar ilaçların emilimi, dağılımı, metabolizması ve atılımı gibi farmakokinetik süreçleri ile toksisite risklerini öngörmede kritik rol oynar. Yapılan araştırmalar; floropirimidin grubu kemoterapötiklerin eliminasyonundan sorumlu DPYD gen polimorfizmlerinin şiddetli ve ölümcül yan etkilerle ilişkili olduğunu, benzer şekilde irinotekan metabolizmasında görevli UGT1A1*28 varyantının nötropeni ve diyare riskini önemli ölçüde artırdığını göstermektedir. Ayrıca meme kanseri tedavisinde sıkça kullanılan tamoksifenin aktif metaboliti endoksifene dönüşümü CYP2D6 enzim aktivitesine bağlı olup, zayıf metabolize edici genotipe sahip hastalarda terapötik faydanın azaldığı ve sağkalım sürelerinin kısaldığı saptanmıştır. Lapatinib ilişkili hepatotoksisitede HLA varyantlarının, yüksek doz metotreksat uygulamasında ise SLCO1B1 polimorfizmlerinin klinik takibi kolaylaştırıcı rolleri kılavuzlara ve FDA uyarılarına yansımıştır. Tüm bu kanıtlara rağmen; maliyet-etkinlik analizlerinin yetersizliği, standardizasyon eksiklikleri ve rehberlerin kısıtlılığı gibi nedenlerle farmakogenetik testlerin klinik kullanımı henüz yaygınlaşmamış olup, rutin uygulamaya entegrasyon için kapsamlı ve randomize çalışmalara ihtiyaç duyulmaktadır.
Pharmacogenetics examines the impact of interindividual genetic variations on drug responses and adverse events, aiming to optimize personalized treatment strategies in oncology. While somatic mutations primarily guide targeted therapies in clinical practice, germline mutations play a pivotal role in pharmacokinetics—affecting drug absorption, distribution, metabolism, and excretion—and predicting toxicity risks. Research demonstrates that polymorphisms in the DPYD gene, responsible for eliminating fluoropyrimidines, are associated with severe and life-threatening toxicities; similarly, the UGT1A1*28 variant impairing irinotecan metabolism significantly elevates risks of neutropenia and diarrhea. In breast cancer management, the conversion of tamoxifen to its active metabolite endoxifen depends heavily on CYP2D6 enzyme activity; poor metabolizers produce lower endoxifen concentrations, resulting in compromised therapeutic efficacy and shorter relapse-free survival. Additionally, specific HLA variants in lapatinib-induced hepatotoxicity and SLCO1B1 polymorphisms in high-dose methotrexate clearance serve as key predictive biomarkers recognized by FDA guidelines. Despite accumulating data, the routine clinical implementation of pharmacogenetic testing remains limited due to design constraints, insufficient cost-effectiveness analyses, and a lack of standardized clinical guidelines, highlighting the necessity for further expansive randomized research to realize individualized oncology care.
Referanslar
Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15): 1200-1205. doi: 10.1001/jama.279.15.1200
Marshall A. Getting the right drug into the right patient. Nat Biotechnol. 1997;15(12): 1249-1252. doi: 10.1038/nbt1197-1249
Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med. 2001;250(3): 186-200. doi: 10.1046/j.1365-2796.2001.00879.x
Davidson RG. Pharmacogenetics: Pharmacogenomics, PDQ Medical Genetics (Ed). Oxford: Elsevier; 2002. p.232.
Gonzalez FJ, Skoda RC, Kimura S, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature. 1988;331(6155): 442-446. doi 10.1038/331442a0
Hertz DL, McLeod HL. Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity. J Hum Genet. 2013;58(6): 346-352. doi: 10.1038/jhg.2013.42
Roden DM, McLeod HL, Relling MV, et al. Pharmacogenomics. Lancet. 2019;394(10197): 521-532. doi: 10.1016/S0140-6736(19)31276-0
FDA: FDA authorizes first direct-to-consumer test for detecting genetic variants that may be associated with medication metabolism. Available at: https://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm624753.htm Accessed February 1, 2019.
Steimer W, Potter JM. Pharmacogenetic screening and therapeutic drugs. Clin Chim Acta. 2002;315(1-2): 137-155. doi: 10.1016/s0009-8981(01)00713-6
Ko TM, Tsai CY, Chen SY, et al. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ. 2015;351: h4848. doi: 10.1136/bmj.h4848 doi: 10.1136/bmj.h4848
Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20): 3219-3226. doi: 10.1200/JCO.2009.27.1825
van Kuilenburg AB, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res. 2000;6(12): 4705-4712.
Sharma BB, Rai K, Blunt H, et al. Pathogenic DPYD variants and treatment-related mortality in patients receiving fluoropyrimidine chemotherapy: a systematic review and metaanalysis. Oncologist. 2021;26(12): 1008-1016. doi: 10.1002/onco.13967
Houtsma D, Guchelaar HJ, Gelderblom H. Pharmacogenetics in oncology: a promising field. Curr Pharm Des. 2010;16 (2): 155-163. doi: 10.2174/138161210790112719
Schwab M, Zanger UM, Marx C, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol. 2008;26(13): 2131-2138. doi: 10.1200/JCO.2006.10.4182
Cohen V, Panet-Raymond V, Sabbaghian N, et al. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidinebased chemotherapy. Clin Cancer Res. 2003;9(5): 1611-1615.
Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004;22(8): 1382-1388. doi: 10.1200/JCO.2004.07.173
Paez D, Tobena M, Fernandez-Plana J, et al. Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype. Br J Cancer. 2019;120(2): 190-195. doi: 10.1038/s41416-018-0348-7
Innocenti F, Grimsley C, Das S, et al. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics. 2002;12(9): 725-733. doi: 10.1097/00008571-200212000-00006
Sharma MR, Joshi SS, Karrison TG, et al. A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. Cancer. 2019;125(10): 1629-1636. doi: 10.1002/cncr.31938
Ocean AJ, Starodub AN, Bardia A, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics. Cancer. 2017;123(19): 3843-3854. doi: 10.1002/cncr.30789
Johnson T, Xu CF, Choueiri TK, et al. Genome-wide association study (GWAS) of efficacy and safety endpoints in pazopanib- or sunitinib-treated patients with renal cell carcinoma (RCC) [abstract]. J Clin Oncol. 2014;32(15): 4503.
Henriksen JN, Bottger P, Hermansen CK, et al. Pazopanib-induced liver toxicity in patients with metastatic renal cell carcinoma: effect of UGT1A1 polymorphism on pazopanib dose reduction, safety, and patient outcomes. Clin Genitourin Cancer. 2020;18(1): 62-68. doi: 10.1016/j.clgc.2019.09.013
Henry NL, Giles JT, Ang D, et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat. 2008;111(2): 365-372. doi: 10.1007/s10549-007-9774-6
Ingle JN, Schaid DJ, Goss PE, et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol. 2010;28(31): 4674-4682. doi: 10.1200/JCO.2010.28.5064
Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. J Clin Oncol. 2012;30(21): 2585-2592. doi: 10.1200/JCO.2011.35.6725
Spraggs CF, Budde LR, Briley LP, et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol. 2011;29(6): 667-673. doi: 10.1200/JCO.2010.31.3197
Spraggs CF, Parham LR, Briley LP, et al. Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes. Pharmacogenomics J. 2018(3);18: 480-486. doi: 10.1038/tpj.2017.39
Schaid DJ, Spraggs CF, McDonnell SK, et al. Prospective validation of HLADRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury. J Clin Oncol. 2014;32(22): 2296-2303. doi: 10.1200/JCO.2013.52.9867
Radtke S, Zolk O, Renner B, et al. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood. 2013;121(26): 5145-5153. doi: 10.1182/blood-2013-01-480335
Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, et al. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;57(4): 612-619. doi: 10.1002/pbc.23074
van Erp NP, Eechoute K, van der Veldt AA, et al. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol. 2009;27(26): 4406-4412. doi: 10.1200/JCO.2008.21.7679
Del Tredici AL, Malhotra A, Dedek M, et al. Frequency of CYP2D6 alleles including structural variants in the United States. Front Pharmacol. 2018;9: 305. doi: 10.3389/fphar.2018.00305
Hoskins JM, Carey LA, McLeod HL. CYP2D6 and Tamoxifen: DNA matters in breast cancer. Nat Rev Cancer. 2009;9(8): 576-586. doi: 10.1038/nrc2683
